Herrlinger U, et al. - In this open-label, randomised, phase 3 trial, researchers examined the effect of lomustine-temozolomide combination therapy compared with standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter. The study included patients from 17 German university hospitals (aged 18–70 years), with newly diagnosed glioblastoma with methylated MGMT promoter, and a Karnofsky Performance Score of 70% and higher. In patients with newly diagnosed glioblastoma with methylated MGMT promoter, lomustine-temozolomide chemotherapy could improve survival vs temozolomide standard therapy. Due to the small size of the trial, the findings should be interpreted cautiously. There were no deaths associated with treatment.